Cheng Yun Wang

US Patent:

7501435, Mar 10, 2009

Filed:

Apr 24, 2007

Appl. No.:

11/789288

Inventors:

Kenneth L. Arrington - Philadelphia PA, US
Edward J. Brnardic - Lansdale PA, US
Vadim Y. Dudkin - Lansdale PA, US
Mark E. Fraley - North Wales PA, US
Shaei Y. Huang - Lansdale PA, US
Cheng Wang - King of Prussia PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/4738
C07D 471/06

US Classification:

514287, 546 64, 544125, 5142332

Abstract:

The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

US Patent:

20090233896, Sep 17, 2009

Filed:

Jun 5, 2006

Appl. No.:

11/921598

Inventors:

Kenneth L. Arrington - Philadelphia PA, US
Vadim Y. Dudkin - Lansdale PA, US
Mark E. Fraley - North Wales PA, US
Jacob M. Hoffman - Lansdale PA, US
Constantine Kreatsoulas - Elkins Park PA, US
Cheng Wang - King of Prussia PA, US

International Classification:

A61K 31/397
C07D 413/14
A61K 31/5377
C07D 401/14
A61K 31/506
C07D 403/00
A61K 31/496
A61P 35/00

US Classification:

5142102, 544121, 5142358, 544124, 5142355, 544333, 514256, 544295, 51425218

Abstract:

The instant invention provides for compounds which comprise substituted pyridyl aminothiazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

US Patent:

20120135977, May 31, 2012

Filed:

Sep 28, 2011

Appl. No.:

13/247009

Inventors:

Douglas C. Beshore - Lower Gwynedd PA, US
Vadim Dudkin - Lansdale PA, US
Robert M. Garbaccio - Lansdale PA, US
Adam W. Johnson - Harleysville PA, US
Scott D. Kuduk - Harleysville PA, US
Jason W. Skudlarek - Audubon PA, US
Cheng Wang - Fort Washington PA, US
Mark E. Fraley - North Wales PA, US

International Classification:

A61K 31/4192
C07D 401/12
A61K 31/4439
C07D 403/12
A61K 31/506
A61K 31/497
C07D 471/04
A61K 31/437
A61K 31/496
C07D 413/12
A61K 31/5377
A61K 31/454
A61K 31/551
A61K 31/55
C07D 417/12
A61K 31/541
A61P 25/00
A61P 25/18
C07D 249/18

US Classification:

51421018, 514359, 548259, 5462684, 514338, 544333, 544316, 514256, 514274, 544405, 51425505, 546121, 514300, 544366, 51425406, 544132, 5142342, 546199, 514321, 540575, 514218, 51421021, 540524, 51421208, 544 582, 5142285

Abstract:

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

US Patent:

20120149677, Jun 14, 2012

Filed:

Aug 16, 2010

Appl. No.:

13/391315

Inventors:

Vadim Y. Dudkin - West Point PA, US
Mark E. Fraley - West Point PA, US
Cheng Wang - West Point PA, US
Robert M. Garbaccio - West Point PA, US
Douglas C. Beshore - West Point PA, US
Scott K. Kuduk - West Point PA, US
Jason W. Skudlarek - West Point PA, US

International Classification:

A61K 31/4439
C07D 403/12
C07D 495/04
C07D 403/14
C07D 401/14
C07D 417/14
A61K 31/497
A61K 31/4709
A61K 31/506
A61K 31/519
A61K 31/444
A61K 31/541
A61K 31/438
A61P 25/00
A61P 25/18
C07D 401/12

US Classification:

51421016, 5462684, 544405, 546157, 544310, 544316, 544278, 544319, 546256, 544238, 544 582, 540575, 540492, 514338, 51425505, 514312, 514274, 5142601, 514269, 514333, 5142285, 51421021, 51421018

Abstract:

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

US Patent:

20220242847, Aug 4, 2022

Filed:

May 18, 2020

Appl. No.:

17/611448

Inventors:

Antonella CONVERSO - West Point PA, US
Abdellatif EL MARROUNI - West Point PA, US
Ashley FORSTER - West Point PA, US
Jessica L. FRIE - West Point PA, US
David N. HUNTER - West Point PA, US
Cheng WANG - West Point PA, US
Deping WANG - West Point PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/06
C07D 401/14
A61K 45/06
A61K 31/506
A61P 31/18

Abstract:

The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

US Patent:

20230022625, Jan 26, 2023

Filed:

Sep 30, 2022

Appl. No.:

17/957470

Inventors:

- Grand Cayman, KY
Lingyuan KE - Los Angeles CA, US
Pankesh JHAVERI - Los Angeles CA, US
Haoyu JIANG - Los Angeles CA, US
Yan YAN - Los Angeles CA, US
Fan GAO - Los Angeles CA, US
Cheng WANG - Los Angeles CA, US
Junfu CHEN - Los Angeles CA, US

International Classification:

G06Q 30/02

Abstract:

A method is proposed for providing a content page in an application. In the method, a media item is generated, and the media item is associated with respective resources in a resource list that is received from a resource provider. The media item is presented in the application. A content page is caused to be displayed in response to detecting an interaction event of a user of the application with the media item, the content page including respective content items for the respective resources. Therefore, the media item and the content page are generated and displayed in an automatic way for the one or more resource providers without any label work from the resource providers.

US Patent:

20210008055, Jan 14, 2021

Filed:

Jul 28, 2020

Appl. No.:

16/940943

Inventors:

- Rahway NJ, US
Mark E. Fraley - North Wales PA, US
Steven N. Gallicchio - Horsham PA, US
Anthony Ginnetti - Perkasie PA, US
Helen J. Mitchell - Richboro PA, US
Daniel V. Paone - Lansdale PA, US
Donnette D. Staas - Harleysville PA, US
Cheng Wang - Fort Washington PA, US
C. Blair Zartman - Hatfield PA, US

International Classification:

A61K 31/4545
A61K 31/435
A61K 31/438
C07D 471/10
C07D 471/20

Abstract:

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

US Patent:

20200216860, Jul 9, 2020

Filed:

Sep 5, 2018

Appl. No.:

16/644411

Inventors:

- Tarrytown NY, US
Andrew J. MURPHY - Croton-on-Hudson NY, US
Cheng WANG - White Plains NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 15/86
C12N 9/22

Abstract:

The invention provides a recombinant RNA molecule comprising (i) a sequence of a gene-editing molecule mRNA, or a sequence of a functional fragment or derivative thereof, and (ii) at least one sequence of a coding or non-coding enrichment RNA, or a sequence of a functional fragment or derivative thereof, wherein the enrichment RNA, or functional fragment or derivative thereof, is capable of enhancing inclusion of the gene-editing molecule mRNA, or functional fragment or derivative thereof, into a retroviral particle. The invention provides a method of producing the retroviral particles of the invention, the method comprising culturing a packaging cell in conditions sufficient for the production of a plurality of retroviral particles.